It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Dysregulated mitochondrial fusion and fission has been implicated in the pathogenesis of numerous diseases. We have identified a novel function of the p53 family protein TAp73 in regulating mitochondrial dynamics. TAp73 regulates the expression of Optic Atrophy 1 (OPA1), a protein responsible for controlling mitochondrial fusion, cristae biogenesis and electron transport chain function. Disruption of this axis results in a fragmented mitochondrial network and an impaired capacity for energy production via oxidative phosphorylation. Owing to the role of OPA1 in modulating cytochrome c release, TAp73−/− cells display an increased sensitivity to apoptotic cell death, e.g., via BH3-mimetics. We additionally show that the TAp73/OPA1 axis has functional relevance in the upper airway, where TAp73 expression is essential for multiciliated cell differentiation and function. Consistently, ciliated epithelial cells of Trp73−/− (global p73 knock-out) mice display decreased expression of OPA1 and perturbations of the mitochondrial network, which may drive multiciliated cell loss. In support of this, Trp73 and OPA1 gene expression is decreased in chronic obstructive pulmonary disease (COPD) patients, a disease characterised by alterations in mitochondrial dynamics. We therefore highlight a potential mechanism involving the loss of p73 in COPD pathogenesis. Our findings also add to the growing body of evidence for growth-promoting roles of TAp73 isoforms.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 University of Cambridge, MRC Toxicology Unit, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); AstraZeneca, Safety Sciences, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, Cambridge, UK (GRID:grid.417815.e) (ISNI:0000 0004 5929 4381)
2 University of Cambridge, MRC Toxicology Unit, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)
3 University of Cambridge, MRC Toxicology Unit, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); University of Rome “Tor Vergata”, Department of Experimental Medicine, Rome, Italy (GRID:grid.6530.0) (ISNI:0000 0001 2300 0941)
4 University of Cambridge, MRC Toxicology Unit, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); University of Konstanz, Division for Systems Toxicology, Department of Biology, Konstanz, Germany (GRID:grid.9811.1) (ISNI:0000 0001 0658 7699)